Gilead Sciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Gilead Sciences yıllık ortalama 8.3% oranında kazançlarını artırırken, Biotechs sektöründe kazançlar growing at 7.7% annual. Gelirler growing yılda ortalama 5.5% oranında artmaktadır. Gilead Sciences'in özkaynak karlılığı 25.8% ve net marjı 20%'dir.

Anahtar bilgiler

8.3%

Kazanç büyüme oranı

9.1%

EPS büyüme oranı

Biotechs Sektör Büyümesi	18.9%
Gelir büyüme oranı	5.5%
Özkaynak getirisi	25.8%
Net Marj	20.0%
Son Kazanç Güncellemesi	30 Jun 2023

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Gilead Sciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

BRSE:000935700 Gelir, gider ve kazançlar (USD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Jun 23	27,382	5,484	6,401	5,557
31 Mar 23	27,043	5,583	5,909	5,259
31 Dec 22	27,281	4,592	5,673	4,977
30 Sep 22	27,136	3,334	5,303	4,746
30 Jun 22	27,515	4,137	5,280	4,727
31 Mar 22	27,472	4,515	5,274	4,714
31 Dec 21	27,305	6,225	5,246	4,601
30 Sep 21	27,482	7,394	5,083	4,655
30 Jun 21	26,638	5,162	4,999	4,713
31 Mar 21	25,564	301	4,887	4,924
31 Dec 20	24,689	123	5,112	4,927
30 Sep 20	23,147	1,268	4,625	4,560
30 Jun 20	22,174	-257	4,571	4,432
31 Mar 20	22,716	4,962	4,427	4,002
31 Dec 19	22,449	5,386	4,381	4,055
30 Sep 19	22,365	2,693	4,308	4,086
30 Jun 19	22,357	5,955	4,204	3,995
31 Mar 19	22,320	5,892	4,089	4,318
31 Dec 18	22,127	5,455	4,056	3,920
30 Sep 18	22,281	1,587	4,177	4,218
30 Jun 18	23,197	2,208	4,108	4,068
31 Mar 18	24,690	3,464	4,025	3,740
31 Dec 17	26,107	4,628	3,878	3,734
30 Sep 17	27,478	11,601	3,618	3,591
30 Jun 17	28,466	12,213	3,570	3,826
31 Mar 17	29,101	12,637	3,563	4,446
31 Dec 16	30,390	13,501	3,398	4,666
30 Sep 16	31,576	15,076	3,472	4,416
30 Jun 16	32,371	16,346	3,544	4,135
31 Mar 16	32,839	17,341	3,466	3,469
31 Dec 15	32,639	18,108	3,426	3,014
30 Sep 15	31,447	16,912	3,236	2,952
30 Jun 15	29,194	15,043	3,278	2,839
31 Mar 15	27,485	14,207	3,080	2,608
31 Dec 14	24,890	12,101	2,983	2,854
30 Sep 14	20,696	9,406	2,561	2,409
30 Jun 14	17,437	7,463	2,023	2,295
31 Mar 14	13,669	4,580	1,814	2,220
31 Dec 13	11,202	3,075	1,699	2,120
30 Sep 13	10,585	3,046	1,538	1,952
30 Jun 13	10,229	2,933	1,451	1,902
31 Mar 13	9,867	2,872	1,379	1,785
31 Dec 12	9,702	2,592	1,280	1,652
30 Sep 12	9,315	2,494	1,315	1,622

Kaliteli Kazançlar: 000935700 yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: 000935700 'nin mevcut net kar marjları (20%) geçen yılın (15%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 000935700 şirketinin kazancı son 5 yılda yılda 8.3% oranında arttı.

Büyüme Hızlandırma: 000935700 'un son bir yıldaki kazanç büyümesi ( 32.6% ) 5 yıllık ortalamasını (yıllık 8.3% ) aşıyor.

Kazançlar vs. Sektör: 000935700 geçen yılki kazanç büyümesi ( 32.6% ) Biotechs sektörünün -18.2% değerini aştı.

Özkaynak Getirisi

Yüksek ROE: 000935700 'nin Özsermaye Getirisi ( 25.8% ) yüksek olsa da, bu ölçüm yüksek borç seviyeleri nedeniyle çarpıktır.

Gilead Sciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 5/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Recent updates

Gilead's Livdelzi (Seladelpar) Demonstrated A Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis

Gilead Sciences, Inc. Presents Full Purpose 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow

Gilead Sciences, Inc. Declares Quarterly Dividend for the Fourth Quarter of 2024, Payable on December 30, 2024

Gilead Sciences, Inc. and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48

Gilead Sciences, Inc. to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024

Gilead Presents Additional Efficacy, Safety and Demographic Data from Purpose 2 Trial At 5Th Hiv Research for Prevention Conference

Gilead’S Livdelzi (Seladelpar) Granted Accelerated Approval for Primary Biliary Cholangitis by U.S. FDA

Gilead Sciences, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Merdad Parsey to Leave Gilead Sciences, Inc. as Chief Medical Officer, Effective Early 2025

Gilead Sciences, Inc Announces New Data Support the Use of BICtegravir Tablet Regimen to Treat People with HIV and Individuals with HIV/HBV-Coinfection in Asia

Gilead Sciences, Inc. Announces Topline Results from an Interim Analysis of Its Pivotal, Phase 3 Purpose 1 Trial

Gilead Sciences, Inc. Announces Data from the Phase 2b MYR204 Open-Label Study

Gilead Sciences, Inc. Announces Two-Year Interim Results from the Ongoing Assure Study of Investigational Seladelpar for the Treatment of Primary Biliary Cholangitis (Pbc), A Rare, Chronic Inflammatory Liver Disease

Gilead and Arcus Announces Etrumadenant Plus Zimberelimab Regimen Significantly Reduced the Risk of Death in Third-Line Metastatic Colorectal Cancer

Gilead Sciences, Inc. Announces Detailed Results from the Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Provides Update on Phase 3 Tropics-04 Study

Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program

Gilead Sciences, Inc. Announces U.S. Food and Drug Administration Approve Biktarvy® Label Update With Data for Pregnant Adults With HIV

Gilead Sciences, Inc. to Report Q1, 2024 Results on Apr 25, 2024

Gilead Sciences, Inc., Annual General Meeting, May 08, 2024

FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic Hbv Infection in Pediatric Patients as Young as Six

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

Gilead Sciences, Inc. Announces Retirement of Kevin E. Lofton from the Board, Effective May 8, 2024

Gilead and Merck Announce Phase 2 Data Showing an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression at Week 24

Gilead Sciences, Inc.'s Innovative HIV Treatment Research Pipeline Aims to Address Unmet Needs and Advance Public Health

Gilead Sciences, Inc. announced that it has received $210 million in funding from Abingworth LLP

Gilead Sciences, Inc. to Present Late-Breaking Data and Real-World Evidence Highlighting Innovative Antiviral Portfolio and Research Pipeline At CROI 2024

Gilead Sciences, Inc. (NasdaqGS:GILD) entered into an Agreement and Plan of Merger to acquire CymaBay Therapeutics, Inc. (NasdaqGS:CBAY) for $3.7 billion.

Gilead Sciences, Inc. Provides Earnings Guidance for the Full Year 2024

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. Appoints Ted Love to Board of Directors

Gilead Sciences, Inc. to Report Q4, 2023 Results on Feb 06, 2024

Gilead Provides Update on Phase 3 Evoke-01 Study

Gilead Sciences, Inc. Announces U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy to Include Overall Survival Data

Gilead Sciences, Inc. Revises Earnings Guidance for the Year 2023

Gilead Sciences, Inc. and Arcus Biosciences, Inc. Announces New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin